AstraZeneca Pharma India Ltd. is engaged in the manufacture, distribution, and marketing of pharmaceutical products and clinical trial services. The company is headquartered in Bangalore, Karnataka and currently employs 947 full-time employees. The firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas, such as oncology, cardiovascular, renal and metabolism, and respiratory. The company also provides clinical trial services. Its cardiovascular disease and diabetic medicine brands include Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL and Xigduo XR. Its respiratory medicine brands include Symbicort and FASENRA. Its oncology medicine brands include LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex and Arimidex. The company provides services, such as self-management, diabetes diet and nutrition plans, and free telephonic counseling to patients. The company operates in over 100 countries.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.